公开(公告)号：KR1020120129121A

公开(公告)日：2012-11-28

申请号：KR1020110047181

申请日：2011-05-19

Applicant: 가톨릭대학교 산학협력단

Inventor： 박성환 ,  조미라 ,  곽승기 ,  박미경 ,  이동건 ,  박은미 ,  고용송 ,  김윤근 ,  장수철

IPC: A61K31/519 ,  A61K31/505 ,  A61K9/127 ,  A61P29/00

CPC classification number: A61K31/519 ,  A61K9/127 ,  A61K31/505 ,  C12N5/06 ,  C12N5/0645

Abstract: PURPOSE: An immunotherapeutic agent containing a cell suspension and methotrexate is provided to enhance methotrexate transfer rate to a target site and to effectively suppress TNF-alpha generation. CONSTITUTION: An immunotherapeutic agent of a nanosome form contains a cell suspension and methotrexate. The cell suspension is a cell membrane in cell lysate. A composition for preventing or treating immune diseases contains an immunotherapeutic agent. The immune diseases are autoimmune diseases, inflammatory diseases, or cell, tissue, or organ transplantation rejection. [Reference numerals] (AA) MTX-containing nanosome

Abstract translation: 目的：提供含有细胞悬浮液和甲氨蝶呤的免疫治疗剂，以增强甲氨蝶呤转移到靶位点并有效抑制TNF-α的产生。 构成：纳米体形式的免疫治疗剂含有细胞悬浮液和甲氨蝶呤。 细胞悬浮液是细胞裂解液中的细胞膜。 用于预防或治疗免疫疾病的组合物含有免疫治疗剂。 免疫疾病是自身免疫性疾病，炎性疾病或细胞，组织或器官移植排斥反应。 （AA）含MTX的纳米体

公开(公告)号：KR1020120095320A

公开(公告)日：2012-08-28

申请号：KR1020120016400

申请日：2012-02-17

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  조석구 ,  박민정 ,  임정연 ,  이성희 ,  임건일

IPC: A61K31/203 ,  A61K31/07 ,  A61P29/00 ,  A61P35/00

Abstract: PURPOSE: A cytoprotection composition for toxicity suppression of natural killer cells including retinal or retinoic acid are provided to reduce or suppress toxicity of the natural killer cells by including T-cells. CONSTITUTION: A cytoprotection composition for toxicity suppression of natural killer cells includes retinal or retinoic acid as an active ingredient. The retinal or retinoic acid suppresses or prevent the cytotoxin of the natural killer cell as reduction. 0.1-5 microM of the retinal or retinoic acid is included. The cytoprotection composition for toxicity suppression of natural killer cells comprises T-cells which are differentiated by processing the retinal or the retinoic acid and human adipose derived mesenchymal stem cells. The differentiated Thymusdependentlymphocyte(treg cell) and the human adipose derived mesenchymal stem cells are included at a rate of 1:0.01-1:0.03.

Abstract translation: 目的：提供用于毒性抑制天然杀伤细胞（包括视网膜或视黄酸）的细胞保护组合物，以通过包括T细胞来减少或抑制天然杀伤细胞的毒性。 构成：用于毒性抑制天然杀伤细胞的细胞保护组合物包括视黄醛或视黄酸作为活性成分。 视网膜或视黄酸抑制或预防自然杀伤细胞的细胞毒素作为还原。 包括0.1-5微米的视网膜或视黄酸。 用于天然杀伤细胞毒性抑制的细胞保护组合物包括通过加工视网膜或视黄酸和人脂肪来源的间充质干细胞分化的T细胞。 分化的胸腺依赖性淋巴细胞（treg细胞）和人脂肪来源的间充质干细胞以1:0.01-1:0.03的比率包含。